Tags

Type your tag names separated by a space and hit enter

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature.
J Crohns Colitis. 2019 Oct 28; 13(11):1470-1473.JC

Abstract

Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands. Division of Gastroenterology and Hepatology, VieCuri Medical Center, Venlo, The Netherlands.Division of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands.Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.

Pub Type(s)

Case Reports
Journal Article
Review

Language

eng

PubMed ID

31116402

Citation

Smeets, Fabiënne G M., et al. "Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease On Long-standing Immunosuppressive Medication During Ustekinumab Treatment: a Case Report and Review of the Literature." Journal of Crohn's & Colitis, vol. 13, no. 11, 2019, pp. 1470-1473.
Smeets FGM, Liedorp PR, van der Poel M, et al. Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. J Crohns Colitis. 2019;13(11):1470-1473.
Smeets, F. G. M., Liedorp, P. R., van der Poel, M., Miclea, R. L., Masclee, A. A. M., & Pierik, M. (2019). Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. Journal of Crohn's & Colitis, 13(11), 1470-1473. https://doi.org/10.1093/ecco-jcc/jjz084
Smeets FGM, et al. Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease On Long-standing Immunosuppressive Medication During Ustekinumab Treatment: a Case Report and Review of the Literature. J Crohns Colitis. 2019 Oct 28;13(11):1470-1473. PubMed PMID: 31116402.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. AU - Smeets,Fabiënne G M, AU - Liedorp,Paulien R, AU - van der Poel,Marjolein, AU - Miclea,Razvan L, AU - Masclee,Ad A M, AU - Pierik,Marieke, PY - 2019/5/23/pubmed PY - 2020/3/31/medline PY - 2019/5/23/entrez KW - Crohn’s disease KW - Ustekinumab KW - lymphoma SP - 1470 EP - 1473 JF - Journal of Crohn's & colitis JO - J Crohns Colitis VL - 13 IS - 11 N2 - Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab. SN - 1876-4479 UR - https://www.unboundmedicine.com/medline/citation/31116402/Anaplastic_Large_Cell_T_Cell_Lymphoma_in_a_Patient_With_Severe_Therapy_refractory_Crohn's_Disease_on_Long_standing_Immunosuppressive_Medication_During_Ustekinumab_Treatment:_A_Case_Report_and_Review_of_the_Literature_ L2 - https://academic.oup.com/ecco-jcc/article-lookup/doi/10.1093/ecco-jcc/jjz084 DB - PRIME DP - Unbound Medicine ER -